Energy Fuels recently reported that it exceeded its 2025 uranium production, mined ore, and uranium concentrate sales ...

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...

Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who ...

A controversial Hepatitis B vaccine safety trial will go on as planned in Africa, amid concerns over its ethics and design ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable advanced cutaneous melanoma with patient enrolment planned to commence in H1 ...

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1, their Phase 1/2 ...

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (Energy Fuels or the Company), a leading U.S. producer of uranium, rare earth elements (REEs), and other critical materials, today released the results of a ...

The city-based Inter-University Centre for Astronomy and Astrophysics (IUCAA) has developed an indigenous technology called ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...